Recent Company News

• 12:12 PM ET Oct 23, 2025
  

  Follow-up: FDA approves efficacy supplment for Vyepti (DKK 46.30, 0.00)

• 04:32 PM ET Oct 20, 2025
  

  Teva Pharmaceutical and Prestige Biopharma enter license agreement for Tuznue commercialization in Europe ($19.42, 0.00)

• 04:30 PM ET Oct 20, 2025
  

  Teva and Prestige Biopharma Enter License Agreement for Tuznue(R) Commercialization in Europe

• 08:54 AM ET Oct 17, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:10 AM ET Oct 17, 2025
  

  EMA CHMP publishes summary of opinions for October 2025 meeting

• 06:29 AM ET Oct 17, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Teva's Austedo intended for the treatment of adults with moderate to severe tardive dyskinesia ($19.63, 0.00)

• 02:07 AM ET Oct 13, 2025
  

  MedinCell announces FDA approves expanded indication for UZEDY (risperidone) extended-release Injectable suspension as a treatment for adults living with bipolar I disorder (€27.44, 0.00)

• 03:03 PM ET Oct 10, 2025
  

  Teva Pharmaceutical announces FDA approves expanded indication for UZEDY extended-release injectable suspension as treatment for adults living with bipolar I disorder ($19.97, -0.07)

• 03:00 PM ET Oct 10, 2025
  

  FDA Approves Expanded Indication for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

• 04:59 PM ET Oct 09, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market